(19)
(11) EP 2 326 632 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
09.08.2017 Bulletin 2017/32

(45) Mention of the grant of the patent:
31.05.2017 Bulletin 2017/22

(21) Application number: 09812208.8

(22) Date of filing: 03.09.2009
(51) International Patent Classification (IPC): 
C07D 277/36(2006.01)
A61P 3/10(2006.01)
A61P 9/10(2006.01)
A61P 25/28(2006.01)
 C07D 277/32(2006.01)
A61K 31/427(2006.01)
A61P 25/02(2006.01)
(86) International application number:
PCT/US2009/055868
(87) International publication number:
WO 2010/028132 (11.03.2010 Gazette 2010/10)

(54)

NOVEL CHOLINE COCRYSTAL OF EPALRESTAT

NEUES CHOLIN-KOKRISTALL VON EPALRESTAT

NOUVEAUX CO-CRISTAUX DE CHOLINE ET D'ÉPALRESTAT

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 06.09.2008 US 94904 P

(43) Date of publication of application:
01.06.2011 Bulletin 2011/22

(73) Proprietor: Bionevia Pharmaceuticals, Inc.
Cambridge, MA 02138 (US)

(72) Inventors:
  • KALOFONOS, Isabel
    Cambridge MA 02138 (US)
  • STAHLY, G., Patrick
    West Lafayette IN 47906 (US)
  • MARTIN-DOYLE, William
    Cambridge MA 02141 (US)
  • KALOFONOS, Dimitris
    Cambridge MA 02138 (US)
  • STULTS, Jeffrey, S.
    West Lafayette IN 47906 (US)
  • HOUSTON, Travis, L.
    Lafayette IN 47909 (US)

(74) Representative: Cottrill, Emily Elizabeth Helen 
A.A. Thornton & Co. 10 Old Bailey
London EC4M 7NG
London EC4M 7NG (GB)


(56) References cited: : 
JP-A- 2004 210 703
JP-A- 2005 298 424
US-A1- 2004 176 335
 JP-A- 2004 210 703
JP-A- 2007 099 680
US-A1- 2005 181 041
   
  • SETOUE MINORU ET AL: "Hyperhomocysteinemia induced by guanidinoacetic acid is effectively suppressed by choline and betaine in rats", BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, vol. 72, no. 7, July 2008 (2008-07), pages 1696-1703, XP002673857, ISSN: 0916-8451
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).